Question · asked by 1 review
Betahistine vs placebo/no treatment: Serious adverse events
- Population
- Ménière’s disease
- Intervention
- Betahistine
- Comparison
- placebo/no treatment
- Outcome
- Serious adverse events
It is very uncertain whether betahistine changes serious adverse events compared with placebo/no treatment (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Betahistine vs placebo/no treatment Serious adverse events · Ménière’s disease It is very uncertain whether betahistine changes serious adverse events compared with placebo/no treatment (very low certainty). Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane Headline outcomes only | RR 1.2 [0.63, 2.29] | 1 study · 220 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Systemic pharmacological interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.